India's drug pricing authority (NPPA) just ordered a big price drop for 137 anti-cancer medicines, effective November 9, 2026.
The move limits trade margins at 30% of the MRP, aiming to make life-saving treatments way more affordable and stop huge markups.
Cuts could save patients ₹2,500cr-₹3,541cr annually
These cuts could save patients between ₹2,500 crore and ₹3,541 crore every year, pretty major.
Some drugs such as thiotepa and palbociclib are now over 90% cheaper.
NPPA also told pharmacies and hospitals to clearly display new prices, and anyone can report overcharging using the Pharma Sahi Daam app.